InnoGen Pharmaceuticals


InnoGen Pharmaceuticals
Full Prescribing Info
Clonidine hydrochloride.
Each tablet contains: Clonidine Hydrochloride 75 mcg & 150 mcg.
Pharmacology: Pharmacokinetics: Clonidine is well absorbed from the gastrointestinal tract, and peak plasma concentrations occur about 3 to 5 hours after an oral dose. It is about 20 to 40% protein bound. About 50% of a dose metabolized in the liver. It is excreted in the urine as unchanged drug and metabolites, 40 to 60% of an oral dose being excreted in 24 hours as unchanged drug; about 20% of a dose is excreted in the faeces, probably via enterohepatic circulation. The elimination half-life has been variously reported to range between 6 and 24 hours, extended to up to 41 hours in patients with renal impairment. Clonidine crosses the placenta and is distributed into breast milk.
For the management of hypertension.
Dosage/Direction for Use
Hypertension 50-100 mcg 3 times daily, increased every second or third day; usual maximum dose 1,200 mcg daily.
Special Precautions
Clonidine should be used with caution in patients with cerebrovascular disease, ischaemic heart disease including myocardial infarction, renal impairment, occlusive peripheral vascular disorders such as Raynaud's disease, or those with a history of depression. Clonidine causes drowsiness and patients should not drive or operate machinery where loss of attention could be dangerous. Systemic effects also occur after epidural use and patients should be closely monitored, particularly during the first few days of therapy. Intravenous injections of clonidine should be given slowly to avoid a possible transient presso effects especially in patients already receiving other antihypertensives such as guanethidine or reserpine.
Adverse Reactions
Drowsiness, dry mouth, dizziness, and headache commonly occur during the initial stages of therapy with Clonidine. Constipation is common, and other adverse effects that have been reported include depression, anxiety, fatigue, nausea, anorexia, parotid pain, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, orthostatic hypotension, and dry, itching, or burning sensations in the eye. Fluid retention may occur and is usually transient, but may be responsible for a reduction in the hypotensive effect during continued treatment. Clonidine may cause rashes and pruritus, and these are more common with the use of transdermal delivery systems. Less frequently, bradycardia, including sinus bradycardia with atrioventricular block, other ECG disturbance, heart failure, hallucinations, cramp, Raynaud's syndrome, gynaecomastia, and transient abnormalities, in liver function test have been reported. Large doses have been associated with initial increases in blood pressure and transient hyperglycemia, although these do not persist during continued therapy.
Drug Interactions
The hypertensive effect of Clonidine may be enhanced by diuretics, other antihypertensive, and drugs that cause hypotension. However, beta blockers may exacerbate rebound hypertension following Clonidine withdrawal and tricyclic antidepressants may antagonize the hypotensive effect. The sedative effect of Clonidine may be enhanced by CNS depressants.
Store at temperatures not exceeding 30°C.
MIMS Class
Other Antihypertensives
ATC Classification
C02AC01 - clonidine ; Belongs to the class of imidazoline receptor agonists, centrally-acting antiadrenergic agents. Used in the treatment of hypertension.
Tab 75 mcg x 100's. 150 mcg x 100's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in